Check Out Symposium Presentations from Industry Leaders
Proprietary HT-SPR™ technology
Eli Lilly developed bamlanivimab, the world’s First COVID-19 therapeutic, on the Carterra LSA platform in a 90-day sprint.
Carterra’s high-throughput biology solutions provide breadth and depth to your artificial intelligence and machine learning strategies.
To match our capacity in generating antibody libraries, we use the Carterra LSA for screening and characterization. Its high throughput capabilities match our highly automated antibody production workflow and shift analytics upstream to the very start of our antibody production. We routinely generate binding kinetics on hundreds of clones in parallel, directly from crude antibody or purified samples using minimal sample.
Epitope binning data produced on Carterra’s LSA gives us a detailed picture of the epitope landscape of our antibody libraries quickly using crude samples.
The Carterra technology…gave us the ability to perform very sensitive high-throughput full-kinetic analysis of unpurified bacterial extracts.
The LSA has the throughput to test large numbers of antibodies quickly, and is really good at epitope binning, which other systems do not seem to do as well.
Carterra’s LSA provides the greatest epitope binning capacity available in the biosensor space and it is enabling a paradigm shift here. We know a lot more, sooner, and that makes us more efficient and more productive.
Our LSA is up and running. The first install in Washington State! We’re excited to use it to speed up our therapeutic discovery process.
The Carterra LSA provides a significant increase in throughput for accurate determination of binding kinetics and affinities to help make lead choices much earlier in the discovery process.
We recently joined the Carterra family and installed our LSA…. As the main user of this instrument, I must admit that LSA is a sensitive instrument with many potential applications…your team has done a wonderful job!
View the Webinar